Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGAERX)

Drug Name
AIR-Epinephrine Drug Info
Indication
Disease Entry ICD 11 Status REF
Allergy 4A80-4A85 Discontinued in Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMGAERX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Adrenergic receptor (ADR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Celiprolol hcl DMD5LBX Hypertension BA00-BA04 Approved [3]
Ovine corticotropin-releasing hormone DME0F98 Cushing disease 5A70 Approved [4]
Befunolol hci DM8WCXM Glaucoma/ocular hypertension 9C61 Approved [3]
Oxilofrine DMRKOS1 Orthostatic hypotension BA21 Approved [4]
Terbutyline DMVPWLZ Hypertension BA00-BA04 Approved [4]
Guanadrel Sulfate DM6S157 Hypertension BA00-BA04 Approved [5]
Dabelotine DMP2SGN Cognitive impairment 6D71 Phase 3 [6]
AR08 DM93CTQ Attention deficit hyperactivity disorder 6A05.Z Phase 2 [7]
PMID30124346-Compound-60TABLE5 DM3QX0R Dyskinesia MB47.4 Patented [8]
Etilefrine DM67PWD Cardiovascular disease BA00-BE2Z Withdrawn from market [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor (ADR) TTVIREA NOUNIPROTAC Agonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019414)
2 Prostaglandin synthesis inhibitors reverse alpha-adrenergic inhibition of acute insulin response to glucose. Am J Physiol. 1980 Dec;239(6):E490-500.
3 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 US patent application no. 2007,0049,576, Neurogenesis by muscarinic receptor modulation.
7 Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov. 2014 June; 9(6): 579-594.
8 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.